Indinavir: A Rare Urinary Stone in HIV-1-Infected Patients – Occurrence and Crystal Properties

R. Tessadri; U.J. Griesser; M. Prillinger; K. Wurst

doi:10.4028/www.scientific.net/MSF.443-444.407

Paper Titles

Synthesis and Crystal Structure of the Double Perovskite Ca_2-xSr_xMnWO₆ (x = 0.0, 0.5, 1.0, 1.5, 2.0)
p.375

Low Temperature Magnetic Structure of CrNiAs
p.379

A Neutron Diffraction Study of Magnetically Ordered Ferroelectric Materials
p.383

The Evolution of the Antiferromagnetic Structure of the Terbium Titanium Oxysulfide Tb₂Ti₂S₂O₅between 5K and 1.4K
p.387

Presence of a Spin Glass State in Antiferromagnetic Tb₂CuIn₃
p.391

Temperature Dependence of Lattice Parameters in Martensite and Effect of the External Magnetic Field on Martensite Structure in Ni₂MnGa Studied In-Situ with Neutron Diffraction
p.397

Thermal Expansion and Excess Properties of Åkermanite-Gehlenite Synthetic Solid Solution Series
p.401

Indinavir: A Rare Urinary Stone in HIV-1-Infected Patients – Occurrence and Crystal Properties
p.407

Docetaxel (Taxotere^® Trihydrate) Forms: Crystal Structure Determination from XRPD & XRSCD Data
p.411

HomeMaterials Science ForumMaterials Science Forum Vols. 443-444Indinavir: A Rare Urinary Stone in HIV-1-Infected...

Indinavir: A Rare Urinary Stone in HIV-1-Infected Patients – Occurrence and Crystal Properties

Abstract:

You might also be interested in these eBooks

$European Powder Diffraction EPDIC 8$ View Preview

Info:

Periodical:

Materials Science Forum (Volumes 443-444)

Pages:

407-410

DOI:

https://doi.org/10.4028/www.scientific.net/MSF.443-444.407

Citation:

Cite this paper

Online since:

January 2004

Authors:

R. Tessadri, U.J. Griesser, M. Prillinger, K. Wurst

Keywords:

Crystal Properties, Crystal Structure, Indinavir, Indinavir Sulphate, Urinary Stones

Export:

RIS, BibTeX

Price:

Permissions CCC:

Request Permissions

Permissions PLS:

Request Permissions

Сopyright:

Citation:

References

[1] J.D. Rich, B. Ramratnam, M. Chinang, K.T. Tashima, J. Urol., 158 (1997), 2228.

Google Scholar

[2] J.B. Kopp, K.D. Miller, J.A.M. Mican, I.M. Feuerstein, E. Vaughan, C. Baker, L.K. Pannell, J. Falloon, Am. Coll Phys., 127 (1997), 119-125.

Google Scholar

[3] M. Daudon, L. Estépa, J.P. Viard, D. Joly, P., Lancet, 349 (1997), 1294-1295.

DOI: 10.1016/s0140-6736(05)62506-8

Google Scholar

[4] Crixivan (Indinavir sulphate), prescribing information, Merck & Co., Inc., NJ, USA, September (2001).

Google Scholar

[5] W.J. Reiter, H. Schön-Pernerstorfer, K. Dorfinger, J. Hofbauer, M. Marberger, J. Urol., 161 (1999), 1082-1084.

Google Scholar

[6] E. Saltel, J.B. Angel, N.G. Futter, W.G. Walsh, K. Orourke, J.E. Mahoney, J. Urol, 164 (2000), 1895-1897.

Google Scholar

[7] J.H. Lin, I.W. Chen, K.J. Vastag, D. Ostovic, Drug Metab. Dispos., 23 (1995), 730-735.

Google Scholar

[8] J.P. Dieleman, S. Salahuddin, Y. S. Hsu, D.M. Burger, I.C. Gyssens, M.C.J.M. Sturkenboom, B.H. Ch. Stricker, D.J. Kok. J. Acquir. Immune Defic. Syndr., 28 (2001), 9-13.

DOI: 10.1097/00042560-200109010-00002

Google Scholar

[9] J. Joost, R. Tessadri R, Urol. Res., Vol. 18/1 (1990), 73.

Google Scholar

[10] J. Joost, R. Tessadri R, Eur. Urol., 9 (1983), 305-311.

Google Scholar

[11] Otwinowski, Z.; Minor, W. Methods Enzymol. (1997), 276, 307.

Google Scholar